Q3 2024 Earnings Forecast for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Issued By HC Wainwright

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities researchers at HC Wainwright increased their Q3 2024 earnings estimates for Day One Biopharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.69) per share for the quarter, up from their prior forecast of ($0.72). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($2.74) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $1.24 EPS.

DAWN has been the topic of a number of other research reports. Needham & Company LLC reissued a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. JPMorgan Chase & Co. raised their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Monday, April 22nd. The Goldman Sachs Group dropped their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Finally, Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Day One Biopharmaceuticals Trading Down 0.2 %

DAWN opened at $16.38 on Thursday. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -6.88 and a beta of -1.44. The company’s 50 day moving average is $15.45 and its 200 day moving average is $14.20. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07).

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the transaction, the chief financial officer now owns 277,754 shares of the company’s stock, valued at $4,235,748.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75. Following the sale, the chief executive officer now owns 721,813 shares in the company, valued at $11,007,648.25. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the sale, the chief financial officer now owns 277,754 shares in the company, valued at approximately $4,235,748.50. The disclosure for this sale can be found here. Insiders have sold 195,247 shares of company stock valued at $3,376,817 over the last 90 days. 8.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Quest Partners LLC bought a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $29,000. China Universal Asset Management Co. Ltd. raised its position in shares of Day One Biopharmaceuticals by 130.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after buying an additional 1,262 shares during the last quarter. Quintet Private Bank Europe S.A. raised its position in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after buying an additional 1,000 shares during the last quarter. Amalgamated Bank increased its position in Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its position in Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after purchasing an additional 2,554 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.